home / stock / mdnaf / mdnaf short
Short Information | Mandatum Pankki Oyj (OTCMKTS:MDNAF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 742,520 |
Total Actual Volume | 1,378,917 |
Short Trends | |
---|---|
Cover Days | 6 |
Short Days | 10 |
No Change Days | 4 |
Averages | |
---|---|
Average Short Volume | 37,126 |
Average Short Percentage | 48.63% |
Is there a MDNAF Short Squeeze or Breakout about to happen?
See the MDNAF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-26-2024 | $1.5696 | $1.61 | $1.627 | $1.55 | 133,481 | 73,806 | 55.29% |
07-25-2024 | $1.4 | $1.53 | $1.6273 | $1.36 | 188,179 | 124,325 | 66.07% |
07-24-2024 | $1.41 | $1.4 | $1.4328 | $1.39 | 43,026 | 19,927 | 46.31% |
07-23-2024 | $1.4215 | $1.42 | $1.44 | $1.4 | 39,904 | 10,014 | 25.1% |
07-22-2024 | $1.35 | $1.43 | $1.43 | $1.35 | 21,489 | 11,839 | 55.09% |
07-19-2024 | $1.4092 | $1.41 | $1.42 | $1.36 | 47,335 | 31,130 | 65.77% |
07-18-2024 | $1.46 | $1.395 | $1.5 | $1.35 | 84,957 | 50,203 | 59.09% |
07-17-2024 | $1.55 | $1.47 | $1.55 | $1.45 | 61,260 | 21,084 | 34.42% |
07-16-2024 | $1.54 | $1.55 | $1.5775 | $1.47 | 122,475 | 57,921 | 47.29% |
07-15-2024 | $1.55 | $1.51 | $1.68 | $1.48 | 76,388 | 57,949 | 75.86% |
07-12-2024 | $1.41 | $1.5531 | $1.6612 | $1.4 | 154,820 | 96,893 | 62.58% |
07-11-2024 | $1.345 | $1.4 | $1.468 | $1.345 | 135,088 | 80,575 | 59.65% |
07-10-2024 | $1.35 | $1.36 | $1.432 | $1.35 | 21,437 | 4,607 | 21.49% |
07-09-2024 | $1.434 | $1.4 | $1.4352 | $1.36 | 31,785 | 12,827 | 40.36% |
07-08-2024 | $1.3814 | $1.43 | $1.44 | $1.3814 | 20,604 | 7,392 | 35.88% |
07-05-2024 | $1.37 | $1.39 | $1.4 | $1.35 | 31,879 | 27,441 | 86.08% |
07-03-2024 | $1.386 | $1.3725 | $1.386 | $1.33 | 19,337 | 2,893 | 14.96% |
07-02-2024 | $1.45 | $1.41 | $1.45 | $1.36 | 67,286 | 19,643 | 29.19% |
07-01-2024 | $1.47 | $1.45 | $1.57 | $1.41 | 45,609 | 7,054 | 15.47% |
06-28-2024 | $1.45 | $1.47 | $1.5 | $1.43 | 32,578 | 24,997 | 76.73% |
News, Short Squeeze, Breakout and More Instantly...
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and best-in-class potential relative to other IL-2 therapies in clinical development ...
- ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA ® , at clinical trial sites in U.S.A., Canada, Australia, and Korea - Monot...
Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half ( hazard ratio: 0.54, 95% confidence interval: 0.34-0.83) versus a propensity balanced external control (EC) arm irrespective of IL...